Corporate Information
A Word from CEO
Management Team
Executive Directors
Representative Director
Taro Ueno
Director and CTO
Tomomitsu Motohashi
Director (administration)
Takayuki Kohara
Outside Directors
Kuniaki Kaga
Audit and Supervisory Committee Member
Yoshiko Akishima
Kenta Nagao
Makiko Yamamoto
Advisor & Collaborations
Advisor
Advanced Telecommunications Research Institute International(ATR)
ATR Brain Information Communication Research Laboratory Group.
Chief
Mitsuo Kawato
Sosei Group Corporation
Chairman of the Board
Shinichi Tamura
Collaborations
We are verifying how efficient our own clinical trial system, in which blockchain technology is implemented, makes clinical trial process (monitoring process etc.). By reducing the burden of operations, we will facilitate clinical trials at ARO (Academic Research Organization) and Clinical Research Core Hospitals.
We are developing data collecting platform for catheter ablation and analyzing the data to provide with treatment suggestions. This is adopted as "Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus" of AMED.
We are developing efficient and highly-trusted monitoring methods in clinical trial process using blockchain technology.
We are developing efficient and highly-trusted disease registry using blockchain technology.
Company
Name
SUSMED, Inc.
Founding
February 23, 2016 (Founded as a limited liability company on July 31, 2015)
Address
MFPR Nihonbashi Honcho Bldg 10F,3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023
CEO
Taro UENO
Business
- Development of smartphone-based therapeutic apps
- Providing therapeutic app development platform
- Development and providing of clinical trial systems with blockchain technology
- Provision of medical data analysis and consulting services through statistical analysis and machine learning
Authorization / Registration
Manufacture of medical devices (Registration No.13BZ201591)
Second-class marketing license for medical devices (Permission number 13B2X10494)
Selling and Leasing Agent of Medical Devices
Access Map
MFPR Nihonbashi Honcho Bldg 10F, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023
JR Sobu Main Line: 2-minute walk from Shin-Nihonbashi station
Tokyo Metro Hibiya Line: 2-minute walk from Kodenmacho station
Tokyo Metro Ginza Line: 7-minute walk from Mitsukoshimae station
History
July 2015
Established as a limited liability company
February 2016
Changed to a joint-stock company
September 2016
Commenced a clinical trial at two facilities in Japan using a smartphone app for treating insomnia
December 2016
Increased capital by approximately JPY 70 million by allocation of new shares to Beyond Next Ventures, Inc.
June 2018
Increased capital by approximately JPY 720 million by allocation of new shares to multiple companies
February 2019
Launched DTx development support services
May 2019
Launched automated analytics business with machine learning
July 2019
Selected as "J-Startup", supporting program for startups by METI, JETRO, NEDO
May 2020
Entered into a capital and business alliance with SUZUKEN CO., LTD.
August 2020
Entered into a capital and business alliance with SUMITOMO CORPORATION and Nippon Chemiphar CO., LTD., respectively
September 2020
Entered into a capital and business alliance with Sawai Pharmaceutical Co., Ltd.
October 2020
Entered into a business alliance with CMIC Co., Ltd. regarding DTx development support
December 2020
Replacement of the monitoring process in clinical trials with the use of blockchain technology was approved by the METI and the MHLW
December 2020
Increased capital by approximately JPY 1.5 billion by allocation of new shares to multiple companies
February 2021
Started a joint development of a DTx app for patients with chronic kidney disease with Tohoku University and the Japanese Society of Renal Rehabilitation
June 2021
Entered into a business alliance with EPS Holdings, Inc. to achieve efficient clinical trials using blockchain technology
July 2021
Started a joint research with National Cancer Center Hospital East to optimize constipation treatment
December 2021
Listed on Tokyo Stock Exchange Mothers
December 2021
Entered into commercialization agreement with SHIONOGI about DTx for Insomnia
February 2022
Completed market authorization approval of DTx for Insomnia
April 2022
Transitioned to a listing on the Growth Market of the TSE in connection with TSE market restructuring
May 2022
Adopted a joint research with National Center of Neurology and Psychiatry as AMED program
June 2022
Entered into an agreement with Aculys Pharma, Inc. about the world’s first clinical trial utilizing blockchain technology
November 2022
Entered into an agreement with KYORIN Pharmaceutical Co., LTD. about co-development of DTx
February, 2023
SUSMED Med CBT-i® App for Insomnia obtained regulatory approval from the Ministry of Health, Labour and Welfare
September 2023
Signed a memorandum of understanding with Tohoku University to build a venous disease registry with blockchain technology
September 2023
Entered into an agreement with ASKA Pharmaceutical Co., Ltd. for joint R&D and marketing of a DTx app in the obstetrics and gynecology field
February 2024
Clinical Development Department designated by the Ministry of Education, Culture, Sports, Science and Technology as a research institution stipulated under the Regulations for Handling Grants-in-Aid for Scientific Research
August 2024
Filed an application for partial changes of SUSMED Med CBT-i, a DTx for insomnia
September 2024
Changed to a company with an audit and supervisory committee